Johnson & Johnson (NYSE:JNJ) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report report published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $215.00 price target on the stock.

A number of other research analysts have also recently commented on the company. Bank of America decreased their price target on Johnson & Johnson from $180.00 to $170.00 and set a neutral rating on the stock in a research report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a hold rating to a buy rating and raised their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a buy rating to a strong-buy rating in a research report on Sunday, June 30th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, Morgan Stanley boosted their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an equal weight rating in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $173.21.

Johnson & Johnson Stock Up 0.8 %

JNJ opened at $160.22 on Monday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $385.60 billion, a P/E ratio of 9.99, a P/E/G ratio of 2.63 and a beta of 0.52. The stock has a fifty day moving average of $150.90 and a 200-day moving average of $153.16.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The company’s revenue was up 4.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Eagle Strategies LLC lifted its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after acquiring an additional 63 shares during the period. Citizens & Northern Corp lifted its stake in Johnson & Johnson by 3.5% in the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock valued at $275,000 after buying an additional 63 shares during the period. Alliance Wealth Advisors LLC UT lifted its stake in Johnson & Johnson by 1.4% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock valued at $739,000 after buying an additional 64 shares during the period. Carolinas Wealth Consulting LLC lifted its stake in Johnson & Johnson by 0.4% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after buying an additional 64 shares during the period. Finally, Epic Trust Investment Advisors LLC lifted its stake in Johnson & Johnson by 3.6% in the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after buying an additional 64 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.